Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation


Get volume discounts if you are getting 3 or more clinicians certified
Book a Call

Peptides are legal in Texas when federal law allows the product and the prescriber follows Texas rules on delegation, telemedicine, pharmacy licensing, and clinic ownership. Here is what the Texas Medical Board, the State Board of Pharmacy, and Texas drug law add, including the 2025 med spa and IV therapy changes.

Yes, peptides are legal in Texas when the product has a lawful federal pathway and the clinician prescribing it meets Texas's own rules. An FDA-approved peptide drug or a peptide compounded by a properly licensed pharmacy, prescribed within a valid practitioner-patient relationship, is legal. A peptide sold as "research use only" and injected into a person is illegal in Texas under state drug law as well as federal law.
Federal law decides whether a peptide can reach a patient at all. Texas then decides who may prescribe it and under what agreement, which pharmacies may ship it into the state, who may own the clinic offering it, and which staff may administer it. Most Texas problems with peptides happen in that second layer: a nurse practitioner without a prescriptive authority agreement that covers the drug, an out-of-state pharmacy without a Texas sterile compounding license, or a med spa owned by someone who cannot own a medical practice.
Status as of October 7, 2026. Texas has no peptide-specific statute, and the legislature does not meet again until January 2027. The rules below are Texas's general prescribing, pharmacy, controlled substance, and corporate practice laws as they apply to peptides. For the federal picture (FDA approval, 503A and 503B compounding, FDA's categories, and research use only products), start with our US guide to peptide legality.
Patients. You can lawfully receive a peptide in Texas with a prescription from a Texas-licensed clinician, filled by a pharmacy licensed to serve Texas. Buying an injectable vial online without a prescription is buying an unapproved drug.
Sellers. Selling a peptide for human use in Texas without FDA approval or a valid prescription and licensed pharmacy violates the Texas Food, Drug, and Cosmetic Act. A "research use only" label does not change that when the product is marketed or sold for people.
Clinicians. You can prescribe compounded or FDA-approved peptides within your scope, with an appropriate exam, a Texas license, a qualified pharmacy, and, for NPs and PAs, a prescriptive authority agreement that covers the drug.
| Rule | Source | What it means for peptides |
|---|---|---|
| License for Texas patients | Occupations Code 151.056 | Treating a patient located in Texas, including by telemedicine, requires a Texas license |
| Telemedicine standard of care | Occupations Code 111.005 and 111.007 | Remote care is allowed and held to the same standard as an in-person visit |
| Valid prescription | Occupations Code 562.056 | A pharmacist may not fill a prescription issued without a valid practitioner-patient relationship |
| Nontherapeutic prescribing | Occupations Code 164.053 | Prescribing a drug that is nontherapeutic, or in a manner inconsistent with public welfare, is grounds for discipline |
| NP and PA prescribing | Occupations Code 157.0512 | Only through a written prescriptive authority agreement with a physician, capped at seven NPs and PAs per physician |
| Human growth hormone | Health and Safety Code 481.071 | Controlled in Texas; bodybuilding in a healthy person is not a valid medical purpose |
| Nonresident sterile compounding | Texas State Board of Pharmacy, Class E-S license |
Texas lets clinicians evaluate and prescribe by telemedicine without a prior in-person visit, provided the care meets the same standard as an in-person encounter. Occupations Code section 111.007 says so directly, and it bars licensing boards from imposing a higher standard on telemedicine. Section 111.005 treats a telemedicine relationship as valid when the clinician meets that standard of care.
The standard of care is where peptide programs get into trouble. A physician who prescribes or administers a drug that is "nontherapeutic in nature or nontherapeutic in the manner the drug or treatment is administered or prescribed" commits unprofessional conduct under section 164.053, and so does one who prescribes dangerous drugs or controlled substances "in a manner inconsistent with public health and welfare." Every injectable peptide is a dangerous drug under Texas law, meaning a prescription drug. A questionnaire that produces a peptide order with no documented indication is the kind of prescribing the Texas Medical Board disciplines.
Pharmacists share the responsibility. Under section 562.056, a pharmacist "may not dispense a prescription drug if the pharmacist knows or should know that the prescription was issued without a valid practitioner-patient relationship." A compounding pharmacy that fills high volumes of peptide prescriptions from a telehealth platform with no real evaluation is exposed alongside the prescriber.
The patient's location decides which license you need. Under section 151.056, a physician in another state who treats a patient located in Texas is practicing medicine in Texas. The exceptions cover episodic consultations with Texas physicians and a few institutional arrangements, never a direct-to-patient peptide practice.
Physicians (MDs and DOs) may prescribe any prescription drug within the standard of care, including off-label use of FDA-approved peptide drugs and compounded peptides that have a lawful source.
Nurse practitioners and physician assistants prescribe in Texas only through delegation from a physician. Texas is a restricted practice state for NPs, so there is no independent route. Delegation happens through a prescriptive authority agreement under Occupations Code section 157.0512, which must be in writing and signed by both parties, and must identify the types or categories of drugs the NP or PA may or may not prescribe. A physician may hold agreements with no more than seven NPs and PAs combined, or their full-time equivalent. The physician and the NP or PA must hold documented quality assurance meetings at least monthly.
For a peptide program, the agreement is the document to check first. If it lists permitted categories and peptides fall outside them, or if it excludes compounded injectables, the NP or PA has no authority to prescribe them, however the clinic's marketing reads. Our courses for nurses and NPs and physician assistants cover how to build peptide protocols into these agreements.
Registered nurses cannot prescribe. They may administer a peptide on a valid order from a physician, NP, or PA, which is how most Texas clinics staff injection visits.
This is the sharpest difference between Texas and federal law for anyone running a peptide or hormone program. Federally, human growth hormone is a prescription drug with distribution restrictions but is not a scheduled controlled substance. Texas lists it in Schedule III, alongside anabolic steroids.
Under Health and Safety Code section 481.071, Schedule III human growth hormone may be prescribed, dispensed, or administered only "for a valid medical purpose and in the course of professional practice." The statute then closes the most common nonmedical use: "bodybuilding, muscle enhancement, or increasing muscle bulk or strength" in a person who is in good health "is not a valid medical purpose."
Growth hormone secretagogue peptides are different molecules and are not human growth hormone. The same reasoning still reaches them through section 164.053: a peptide prescribed to a healthy patient purely for muscle gain, with no documented indication, is hard to defend as therapeutic. Document the diagnosis and the monitoring plan for every prescription that touches the growth hormone axis.
Texas layers its own pharmacy licensing on top of federal 503A and 503B rules. The Texas State Board of Pharmacy requires an out-of-state pharmacy to hold a nonresident license (Class E) to ship prescriptions to Texas patients, and a separate nonresident sterile compounding license (Class E-S) to ship sterile preparations, which includes every injectable peptide. A Class E-S pharmacy must be inspected for compliance with the Board's sterile compounding rule, 22 Texas Administrative Code 291.133, and its pharmacist-in-charge must hold a Texas pharmacist license as well as one in the pharmacy's home state. In-state pharmacies that compound sterile preparations carry their own sterile designation, such as Class A-S. Check any pharmacy's licenses on the Board of Pharmacy's site before sending a single prescription.
A license does not guarantee clean product, as 2026 showed. Between August and September, three Texas compounding pharmacies issued nationwide recalls of injectable glutathione, a three-amino-acid peptide widely used in wellness and IV clinics, because of elevated bacterial endotoxin. Victory Medical Center Pharmacy in Austin recalled three lots on August 5 after patients reported fever, chills, tachycardia, and blood pressure changes. Optimal Balance Pharmacy followed on August 19, and Centric Compounding recalled glutathione, Myers' cocktail, and immune blend vials on September 9 after nine adverse event reports, tracing the problem to the glutathione active ingredient itself.
The lesson for a Texas clinic is to ask every compounding pharmacy where its active ingredients come from, whether each lot is tested for endotoxin and sterility, and to see the results. A certificate of analysis for the raw ingredient says nothing about the finished vial.
None of this changes what may be compounded. A Texas-licensed pharmacy still needs a bulk substance that qualifies under federal law, which for most peptides means FDA's interim categories and the 503A Bulks List. Our breakdown of FDA's July 2026 advisory committee meeting covers where those decisions stand.
Texas is restrictive about physicians selling drugs. Under Occupations Code section 158.001, a physician "may supply a patient with any drug, remedy, or clinical supply necessary to meet the patient's immediate needs," but may not "operate a retail pharmacy" without a pharmacy license. Section 158.003 adds a narrow exception for physicians practicing in small rural areas with no pharmacy within 15 miles, who may keep a supply and be reimbursed for it after notifying both boards.
In practice, a Texas clinic can administer a peptide in the office and can send a patient home with what the patient immediately needs. A clinic that stocks multi-week supplies of compounded peptides and sells them at a markup is operating as a pharmacy, and the usual route is a patient-specific prescription filled by a licensed pharmacy instead. Office stock for in-clinic administration generally comes from a 503B outsourcing facility, since a 503A pharmacy compounds against patient-specific prescriptions.
Ownership and the corporate practice of medicine. Texas enforces the corporate practice of medicine doctrine. Only licensed physicians may practice medicine under Occupations Code section 155.001, and the Texas Medical Board has long held that a lay business may not employ physicians to practice medicine, with narrow exceptions such as nonprofit health organizations the Board certifies. A med spa owned by a nurse, an aesthetician, or an investor cannot hire a physician to prescribe peptides for its clients. The common lawful structure is a physician-owned professional entity that owns the clinical side and contracts with a separate management services organization for nonclinical work, without ceding control of medical decisions.
Delegation. The Texas Medical Board repealed its old med spa rule, 22 Texas Administrative Code 193.17, and replaced it with general delegation rules at sections 169.25 through 169.28, effective January 9, 2025. Pages that still cite 193.17 are out of date. Before staff perform a delegated act, a physician, PA, or APRN must establish a practitioner-patient relationship and create a medical record. The delegating physician must ensure the staff member is trained in the procedure, its contraindications, and complication management, and must write or approve written orders that include screening criteria and emergency procedures. A supervising clinician must be on site or immediately available, at least one person on site must hold basic life support training, and the names of the delegating physicians and the Board's complaint notice must be posted in public areas and treatment rooms.
Elective IV therapy and Jenifer's Law. House Bill 3749, known as Jenifer's Law, added Chapter 172 to the Occupations Code effective September 1, 2025. It covers elective IV therapy, meaning fluids, nutrients, or medications given intravenously to relieve temporary discomfort or improve temporary wellness, when it is provided outside a physician's office or a licensed health facility. Only a physician, or a PA or APRN the physician delegates to, may order it. Only a physician, PA, APRN, or registered nurse may administer it, under adequate physician supervision. Unlicensed staff can no longer start drips at a wellness lounge, which matters for any clinic that pairs peptide injections with an IV menu.
Texas's Food, Drug, and Cosmetic Act tracks federal drug law and adds its own enforcement. Health and Safety Code section 431.114 bars anyone from selling, delivering, offering for sale, or giving away a new drug unless FDA has approved it. Subsection (b) goes further: no one may "use in or on human beings" a drug limited to investigational use unless an investigational new drug application has been filed with FDA.
A peptide sold for injection under a "research use only" label is an unapproved new drug, so selling it into Texas for human use violates section 431.114(a), and a clinician who administers one to a patient outside an IND runs into section 431.114(b). The Texas Department of State Health Services enforces the Act independently of FDA's warning letters.
That answers the selling question too. A Texas business can lawfully sell genuine research reagents to laboratories. Selling the same vials to consumers, with dosing guidance, injection supplies, or marketing aimed at people, is selling an unapproved drug in Texas.
For a Texas clinician, the practical rule matches the federal one: never prescribe, administer, or supply a research use only product, and document it as a self-sourced exposure when a patient arrives already using one.
Texas changed two rules that shape peptide programs in 2025. The Texas Medical Board's restructured delegation rules took effect on January 9, 2025, replacing the old med spa rule, and Jenifer's Law took effect on September 1, 2025, limiting who may order and administer elective IV therapy outside medical offices.
The legislature did not meet in regular session in 2026, so this year's changes came from FDA and the market. FDA revised its compounding categories for several peptides and convened its advisory committee in July, and three Texas pharmacies recalled injectable glutathione in August and September. The 90th Legislature convenes in January 2027, and we will update this page if it takes up compounding, med spa, or peptide bills.
Run through these checks for each patient, in addition to the federal checklist in our US guide.
No, when they are FDA-approved drugs or compounded by a licensed pharmacy and prescribed within a valid practitioner-patient relationship. Peptides sold as "research use only" and used in people are illegal under Texas Health and Safety Code section 431.114 and federal law.
Yes, through a prescriptive authority agreement with a physician under Occupations Code section 157.0512. The agreement must identify the drug categories the NP may prescribe, so peptides need to fall within it. Texas does not allow NPs to prescribe independently.
Yes, when a physician-owned entity controls the medical side, a physician, PA, or APRN establishes the patient relationship before any delegated injection, and the delegation follows the Texas Medical Board's written order and posting rules. A med spa owned by a nonphysician cannot employ a physician to prescribe for its clients.
No. Texas allows prescribing after a telemedicine evaluation, provided it meets the same standard of care as an in-person visit. Human growth hormone is controlled in Texas, so prescribing it also requires a valid medical purpose and the controlled substance safeguards that apply to Schedule III drugs.
Only within the drug laws. Licensed pharmacies may dispense compounded peptides on valid prescriptions, and FDA-approved peptide drugs move through normal pharmacy channels. Selling unapproved peptides to consumers for human use, under any label, violates the Texas Food, Drug, and Cosmetic Act.
Only with a Texas license. Texas applies its licensing law based on where the patient is located, and the out-of-state exceptions do not cover direct patient care by telemedicine.
| Out-of-state pharmacies shipping injectables to Texas patients need a Class E-S license |
| In-office drug supply | Occupations Code 158.001 and 158.003 | Physicians may supply drugs for immediate needs but may not run a retail pharmacy, outside a narrow rural exception |
| Delegated procedures | 22 Texas Administrative Code 169.25 to 169.28 | Exam first, written orders, a reachable supervisor, and posted notices when staff perform delegated acts |
| Elective IV therapy | Occupations Code Chapter 172 (Jenifer's Law) | Outside physician offices and licensed facilities, only physicians, PAs, APRNs, and RNs may administer, under physician supervision |
| Unapproved new drugs | Health and Safety Code 431.114 | Selling a new drug without FDA approval, or using an investigational drug in people without an IND, violates Texas law |